ClinicalTrials.gg
CompletedNCT00768079Updated Nov 18, 2020Results posted

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

A Phase 2 interventional study of Placebo and Benralizumab in Asthma, sponsored by MedImmune LLC. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
23rd of 39
110 · median 128
Started
2009
the only one that year
Phase 2
7 of 39
none open now
Registered
3rd of 39
by date
Lead sponsor
5 of 39
MedImmune LLC

Among the 39 studies testing benralizumab in Asthma, this one is the 23rd largest by enrollment, is the only one that started in 2009, is one of 7 in phase 2, and was the 3rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The study will evaluate the effect of two intravenous dose regimens of benralizumab (MEDI-563) on the proportion of adult subjects with asthma exacerbations who required an urgent healthcare visit for treatment of an acute asthma exacerbation.

Read the detailed description

The study will evaluate the effect of two intravenous dose regimens of benralizumab (MEDI-563) (0.3 milligram per kilogram [mg/kg] of body weight and 1.0 mg/kg of body weight) on the proportion of adult subjects with asthma exacerbations (relapse and de novo) who required an urgent healthcare visit for treatment of an acute asthma exacerbation.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Benralizumab
  • MEDI-563
  • Asthma
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18 to 60 years at the time of the administration of product
  • Written and Health Insurance Portability and Accountability Act (HIPAA) authorization (applies to covered entities in the US only) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • Physician-diagnosed asthma with a duration of greater than or equal to (>=) 2 years by medical chart or subject report
  • Had an asthma exacerbation requiring urgent care in the year prior to screening
  • Meets National Heart, Lung, and Blood Institute (NHLBI) for persistent asthma in the 3 months prior to the current urgent healthcare visit
  • Current asthma exacerbation that must have lasted >= 2 hours prior to arrival to the urgent healthcare setting
  • Requires at least 2 treatments of inhaled bronchodilators for the current asthma exacerbation in the urgent healthcare setting or within the emergency medical system (EMS) for >= 1 hour
  • Shows an or PEF of not more than 70 percent (%) predicted after 1 hour of treatment of the current asthma exacerbation
  • Women of , unless surgically sterile (including tubal ligation) and/or at least 2 years , must have used 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted , intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual partner, or sterile sexual partner) from screening through the end of the study (Day 84; Cessation of birth control after this point should be discussed with a responsible physician)
  • Men, unless surgically sterile, must likewise practice 2 effective methods of birth control (condom with spermicide or abstinence) and must use such precautions from Day 0 through Day 84
  • Otherwise healthy by medical history and physical examination
  • A chest x-ray that is normal for an asthmatic population and excludes alternative diagnosis per the investigation
  • Ability to complete the follow-up period until Day 168 as required by protocol
  • The investigator has determined that the subject is clinically stable and the FEV1, is >= 30% predicted prior to receiving investigational product on Day 0.

Exclusion criteria

Exclusion Criteria:

  • Known history of allergy or reaction to any component of the product formulation
  • Acute illness other than asthma at the start of the study
  • Fever more than (>) 38.6 degrees Celsius (C) (>101.5 degrees Fahrenheit [F])
  • Current acute asthma attack is due to aspirin-induced asthma
  • Current asthma episode is an anaphylactoid/anaphylactic reaction presenting with acute bronchospasm
  • Evidence of non-respiratory active infection, including ongoing chronic infection
  • History or current prolonged diarrhea, abdominal pain, and/or blood and mucus in stools or have minor symptoms and have exposure to stream or lake water, been exposed to someone who has a parasitic infection (like a family member), or study subject has traveled outside the United States of America (USA) and/or Canada within the last year
  • Use of medication (except oral prednisone and inhaled and topical ) within 30 days before randomization into the study
  • Have received Xolair within 6 months before randomization into the study
  • Receipt of immunoglobulin or blood products within 30 days before randomization into the study
  • Receipt of any investigational drug therapy within 6 months before the first dose of investigational product in this study through Day 168
  • History of primary immunodeficiency
  • Previous medical history, or evidence, of an intercurrent illness that may compromise the safety of the subject in the study
  • History of clinically significant abnormality on in the opinion of the investigator
  • Pregnancy (must have a negative serum pregnancy test prior to the first dose of investigational product)
  • Breastfeeding or lactating woman
  • History of treatment for alcohol or drug abuse within the past year
  • Diagnosis of (COPD) by a healthcare professional
  • Evidence of any clinically significant systemic disease on physical examination
  • History of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >1 year prior to entry or other treated with apparent success with curative therapy >5 years prior to entry
  • Known exposure to inhaled occupational agents or fumes with an established diagnosis of occupational asthma
  • Any condition (that is, impending ventilatory failure or hemodynamic compromise) that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of study results
  • Any employee of the clinical study site who is involved with the conduct of the study
  • History of cigarette smoking >20 pack years
  • Previously received benralizumab (MEDI-563)
  • Asthma exacerbation due to acute inhalational exposure.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.

    Other: Placebo

  • Experimental
    Benralizumab 0.3 mg/kg

    A single dose of benralizumab (MEDI-563) 0.3 milligram per kilogram (mg/kg) of body weight intravenous infusion over at least 30 minutes on Day 0.

    Biological: Benralizumab

  • Experimental
    Benralizumab 1.0 mg/kg

    A single dose of benralizumab (MEDI-563) 1.0 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.

    Biological: Benralizumab

Interventions

  • OtherPlacebo

    A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.

  • BiologicalBenralizumab

    A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.

    Also known as: MEDI-563

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Asthma Exacerbations at Week 12

    Percentage of participants who required urgent healthcare visit for treatment of acute asthma exacerbation were reported. As per protocol, asthma exacerbation (relapse/de novo) was defined as either 1) increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that did not resolve within 2 hours after use of rescue albuterol or corticosteroids and required an unscheduled medical visit or 2) during scheduled study visit, participant had acute worsening of asthma symptoms and a reduction of greater than or equal to (\>=) 20 percent (%) in Peak Expiratory Flow (PEF) or Forced Expiratory Volume in 1 Second (FEV1), which in the opinion of the investigator required treatment with systemic corticosteroids. Asthma exacerbations were analyzed in a non-adjudicated manner (by investigator), which were then adjudicated in a blinded fashion by the sponsor medical monitor prior to database lock to determine whether the reported exacerbation met the protocol definition.

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and Day 84 that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Day 0 to Day 84

  2. Percentage of Participants With Asthma Exacerbations at Week 4 and Week 24

    Percentage of participants who required an urgent healthcare visit for treatment of an acute asthma exacerbation were reported. As per protocol, asthma exacerbation (relapse or de novo) was defined as either 1) an increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that did not resolve within 2 hours after the use of rescue albuterol or corticosteroids and required an unscheduled medical visit or 2) during a scheduled study visit, the participant had acute worsening of asthma symptoms and a reduction of \>=20% in PEF or FEV1, which in the opinion of the investigator required treatment with systemic corticosteroids. Asthma exacerbations were analyzed in a non-adjudicated manner (by investigator), which were then adjudicated in a blinded fashion by the sponsor medical monitor prior to database lock to determine whether the reported exacerbation met the protocol definition.

    Time frame: Weeks 4 and 24

  3. Asthma Control Questionnaire (ACQ) Scores

    Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score is the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Results were reported for overall ACQ score and 6 item scores.

    Time frame: Days 0, 7, 42, and 84

  4. Forced Expiratory Volume in 1 Second (FEV1) Recorded at Study Sites

    The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Spirometry was performed with the participant in the sitting position at study sites by the investigator or qualified designee according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. Multiple forced expiratory efforts (at least 2 but no more than 5) were performed for each office spirometry session and the 2 best efforts that met ATS/ERS acceptability and reproducibility criteria were recorded. The best efforts were based on the highest FEV1. The maximum FEV1 of the 2 best efforts was used for the analysis.

    Time frame: Days 0, 7, 42, and 84

  5. Forced Expiratory Volume in 1 Second (FEV1) Recorded at Home

    The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Home peak flow testing for FEV1 was performed every morning while sitting or standing prior to using any medication (if needed) for asthma. Mean FEV1 values for each week were reported starting from Day 1 to Day 84.

    Time frame: Day 1 to Day 84

  6. Peak Expiratory Flow (PEF) Recorded at Home

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Home peak flow testing for PEF was performed every morning while sitting or standing prior to using any medication (if needed) for asthma. Mean PEF values for each week were reported starting from Day 1 to Day 84.

    Time frame: Day 1 to Day 84

  7. Number of Puffs of Rescue Beta-2 Agonist Per Week

    Rescue beta-2 agonist use (total number of puffs for the prior day) was collected daily in the morning by the participants in the electronic daily diary provided to them. Participants were instructed not to collect rescue beta-2 agonist used prior to exercise. Average values for each week were reported starting from Day 1 to Day 84.

    Time frame: Day 1 to Day 84

  8. Number of Participants With Physician Global Assessment (PGA) at Day 42 and Day 84

    Physician Global Assessment (PGA) consisted of a single physician-rated question assessing participant's status as 'excellent', 'good', 'moderate', 'poor', 'worsening' or 'not applicable (NA)'. Number of participants were categorically summarized.

    Time frame: Days 42 and 84

  9. Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Scores

    Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ\[S\]): a 32-item questionnaire that measures the functional impairments experienced by adult participants including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment).

    Time frame: Days 0, 42, and 84

  10. Number of Healthcare Resources Utilized by Resource Type

    Healthcare resource use was summarized by resource type from information on asthma exacerbations, and asthma related medications. Healthcare resource utilization assessed the total number of hospitalizations, urgent care, primary care clinic visits, asthma specialist clinic visits, telephone calls, and home management.

    Time frame: Day 0 to Day 168

  11. Maximum Observed Serum Concentration (Cmax) for Benralizumab

    The Cmax of benralizumab is reported. Non-compartmental pharmacokinetic (PK) analysis was used for evaluation.

    Time frame: Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84

  12. Area Under the Serum Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) for Benralizumab

    AUClast = area under the concentration-time curve from time 0 to last measurable concentration. Non-compartmental PK analysis was used for evaluation.

    Time frame: Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84

  13. Area Under the Serum Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUC [0 - Infinity]) for Benralizumab

    AUC \[0 - infinity\] = Area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity). Non-compartmental PK analysis was used for evaluation.

    Time frame: Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84

  14. Systemic Clearance (CL) for Benralizumab

    Systemic clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Non-compartmental PK analysis was used for evaluation. Clearance was normalized to participant's body weight.

    Time frame: Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84

  15. Terminal Phase Elimination Half-Life (t1/2) for Benralizumab

    Terminal phase elimination half-life is the time measured for the serum concentration to decrease by one half. Non-compartmental PK analysis was used for evaluation.

    Time frame: Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84

  16. Volume of Distribution of the Central Compartment (Vc) for Benralizumab

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Vc = volume of distribution of the central compartment, calculated as Dose/Cmax; where Cmax = maximum observed serum concentration. Non-compartmental PK analysis was used for evaluation. Results were normalized to participant's body weight.

    Time frame: Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84

  17. Volume of Distribution at Steady State (Vss) for Benralizumab

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Vss = steady state volume of distribution, calculated as MRT\*CL, where MRT is the Mean Residence Time and CL is systemic clearance; which is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Non-compartmental PK analysis was used for evaluation. Results were normalized to participant's body weight.

    Time frame: Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84

  18. Number of Participants With Anti-Drug Antibodies to Benralizumab

    Number of participants with anti-drug antibodies to benralizumab is reported.

    Time frame: Day 0 and 84

07

Results

Posted Oct 12, 2020

Participant flow

A total of 110 participants were randomized in the study.

Participant flow — Overall Study
MilestonePlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Started383636
Completed363532
Not completed214
Withdrew: Lost to follow-up204
Withdrew: Participant incarcerated010

Outcome measures

PrimaryPercentage of Participants With Asthma Exacerbations at Week 12

Percentage of participants who required urgent healthcare visit for treatment of acute asthma exacerbation were reported. As per protocol, asthma exacerbation (relapse/de novo) was defined as either 1) increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that did not resolve within 2 hours after use of rescue albuterol or corticosteroids and required an unscheduled medical visit or 2) during scheduled study visit, participant had acute worsening of asthma symptoms and a reduction of greater than or equal to (\>=) 20 percent (%) in Peak Expiratory Flow (PEF) or Forced Expiratory Volume in 1 Second (FEV1), which in the opinion of the investigator required treatment with systemic corticosteroids. Asthma exacerbations were analyzed in a non-adjudicated manner (by investigator), which were then adjudicated in a blinded fashion by the sponsor medical monitor prior to database lock to determine whether the reported exacerbation met the protocol definition.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Asthma Exacerbations at Week 12
percentage of participantsPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Non-adjudicated Exacerbations38.925.041.7
Adjudicated Exacerbations38.925.041.7
Statistical analysis
  • Placebo vs Benralizumab 0.3 mg/kg · Fisher Exact · p = 0.312
  • Placebo vs Benralizumab 1.0 mg/kg · Fisher Exact · p = 1.000
  • Placebo vs Benralizumab 0.3 mg/kg · Fisher Exact · p = 0.312
  • Placebo vs Benralizumab 1.0 mg/kg · Fisher Exact · p = 1.000
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and Day 84 that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Day 0 to Day 84
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
TEAEs303230
TESAEs9811
SecondaryPercentage of Participants With Asthma Exacerbations at Week 4 and Week 24

Percentage of participants who required an urgent healthcare visit for treatment of an acute asthma exacerbation were reported. As per protocol, asthma exacerbation (relapse or de novo) was defined as either 1) an increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that did not resolve within 2 hours after the use of rescue albuterol or corticosteroids and required an unscheduled medical visit or 2) during a scheduled study visit, the participant had acute worsening of asthma symptoms and a reduction of \>=20% in PEF or FEV1, which in the opinion of the investigator required treatment with systemic corticosteroids. Asthma exacerbations were analyzed in a non-adjudicated manner (by investigator), which were then adjudicated in a blinded fashion by the sponsor medical monitor prior to database lock to determine whether the reported exacerbation met the protocol definition.

Time frame:
Weeks 4 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Asthma Exacerbations at Week 4 and Week 24
percentage of participantsPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Week 4: Non-adjudicated Exacerbations22.211.122.2
Week 4: Adjudicated Exacerbations22.211.122.2
Week 24: Non-adjudicated Exacerbations47.236.150.0
Week 24: Adjudicated Exacerbations47.236.150.0
Statistical analysis
  • Placebo vs Benralizumab 0.3 mg/kg · Fisher Exact · p = 0.343
  • Placebo vs Benralizumab 1.0 mg/kg · Fisher Exact · p = 1.000
  • Placebo vs Benralizumab 0.3 mg/kg · Fisher Exact · p = 0.343
  • Placebo vs Benralizumab 1.0 mg/kg · Fisher Exact · p = 1.000
  • Placebo vs Benralizumab 0.3 mg/kg · Fisher Exact · p = 0.474
  • Placebo vs Benralizumab 1.0 mg/kg · Fisher Exact · p = 1.000
  • Placebo vs Benralizumab 0.3 mg/kg · Fisher Exact · p = 0.474
  • Placebo vs Benralizumab 1.0 mg/kg · Fisher Exact · p = 1.000
SecondaryAsthma Control Questionnaire (ACQ) Scores

Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score is the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Results were reported for overall ACQ score and 6 item scores.

Time frame:
Days 0, 7, 42, and 84
Reported as:
Mean · units on a scale
Asthma Control Questionnaire (ACQ) Scores
units on a scalePlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Overall ACQ: Day 03.69 ± 0.823.72 ± 1.183.26 ± 1.27
Overall ACQ: Day 71.89 ± 1.161.89 ± 1.361.52 ± 0.96
Overall ACQ: Day 421.70 ± 1.231.76 ± 1.251.50 ± 1.13
Overall ACQ: Day 841.59 ± 1.231.75 ± 1.331.70 ± 1.12
Night-time waking: Day 03.1 ± 1.43.5 ± 1.82.9 ± 1.7
Night-time waking: Day 71.7 ± 1.61.7 ± 1.71.0 ± 1.0
Night-time waking: Day 421.4 ± 1.61.6 ± 1.51.2 ± 1.4
Night-time waking: Day 841.3 ± 1.41.4 ± 1.61.2 ± 1.2
Symptoms on waking: Day 03.4 ± 1.43.5 ± 1.52.8 ± 1.5
Symptoms on waking: Day 71.8 ± 1.32.0 ± 1.41.4 ± 1.2
Symptoms on waking: Day 421.6 ± 1.31.6 ± 1.31.2 ± 1.0
Symptoms on waking: Day 841.5 ± 1.61.7 ± 1.41.6 ± 1.2
Activity limitation: Day 03.6 ± 1.33.5 ± 1.43.2 ± 1.8
Activity limitation: Day 71.7 ± 1.31.8 ± 1.51.5 ± 1.5
Activity limitation: Day 421.6 ± 1.51.6 ± 1.51.4 ± 1.3
Activity limitation: Day 841.3 ± 1.31.5 ± 1.32.0 ± 1.9
Shortness of breath: Day 04.4 ± 1.04.2 ± 1.33.7 ± 1.5
Shortness of breath: Day 71.9 ± 1.42.1 ± 1.51.8 ± 1.4
Shortness of breath: Day 422.0 ± 1.32.1 ± 1.51.9 ± 1.5
Shortness of breath: Day 841.8 ± 1.32.0 ± 1.41.9 ± 1.4
Wheeze: Day 04.5 ± 1.14.2 ± 1.54.0 ± 1.6
Wheeze: Day 72.6 ± 1.92.2 ± 1.62.0 ± 1.8
Wheeze: Day 422.1 ± 1.52.0 ± 1.51.8 ± 1.5
Wheeze: Day 842.1 ± 1.72.2 ± 1.71.8 ± 1.6
Rescue beta-2 agonist use: Day 03.0 ± 1.33.3 ± 1.63.2 ± 1.5
Rescue beta-2 agonist use: Day 71.7 ± 1.11.6 ± 1.51.3 ± 0.9
Rescue beta-2 agonist use: Day 421.5 ± 1.31.6 ± 1.31.6 ± 1.6
Rescue beta-2 agonist use: Day 841.5 ± 1.21.7 ± 1.41.8 ± 1.3
SecondaryForced Expiratory Volume in 1 Second (FEV1) Recorded at Study Sites

The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Spirometry was performed with the participant in the sitting position at study sites by the investigator or qualified designee according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. Multiple forced expiratory efforts (at least 2 but no more than 5) were performed for each office spirometry session and the 2 best efforts that met ATS/ERS acceptability and reproducibility criteria were recorded. The best efforts were based on the highest FEV1. The maximum FEV1 of the 2 best efforts was used for the analysis.

Time frame:
Days 0, 7, 42, and 84
Reported as:
Mean · liters
Forced Expiratory Volume in 1 Second (FEV1) Recorded at Study Sites
litersPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Day 01.696 ± 0.5231.689 ± 0.6982.067 ± 0.746
Day 72.008 ± 0.6322.003 ± 0.6552.254 ± 0.723
Day 421.962 ± 0.7142.130 ± 0.7132.150 ± 0.723
Day 842.048 ± 0.7612.043 ± 0.7102.209 ± 0.791
SecondaryForced Expiratory Volume in 1 Second (FEV1) Recorded at Home

The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Home peak flow testing for FEV1 was performed every morning while sitting or standing prior to using any medication (if needed) for asthma. Mean FEV1 values for each week were reported starting from Day 1 to Day 84.

Time frame:
Day 1 to Day 84
Reported as:
Mean · liters
Forced Expiratory Volume in 1 Second (FEV1) Recorded at Home
litersPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Day 1 to 71.6346 ± 0.48681.7119 ± 0.63091.8404 ± 0.7222
Day 8 to 141.7800 ± 0.56081.8562 ± 0.64671.7674 ± 0.7305
Day 15 to 211.7024 ± 0.52001.7874 ± 0.65291.8219 ± 0.7241
Day 22 to 281.6751 ± 0.58141.8188 ± 0.64611.8351 ± 0.7107
Day 29 to 351.6446 ± 0.49621.7937 ± 0.62291.7486 ± 0.7093
Day 36 to 421.7230 ± 0.58441.7935 ± 0.63411.7298 ± 0.6923
Day 43 to 491.7326 ± 0.54261.7999 ± 0.67351.7803 ± 0.6655
Day 50 to 561.6965 ± 0.57561.7532 ± 0.65301.7806 ± 0.6558
Day 57 to 631.6600 ± 0.60131.7682 ± 0.66191.8504 ± 0.7636
Day 64 to 701.7218 ± 0.63081.8735 ± 0.77011.7904 ± 0.7959
Day 71 to 771.7180 ± 0.59691.7811 ± 0.67211.7401 ± 0.6891
Day 78 to 841.7591 ± 0.69441.6655 ± 0.60321.7818 ± 0.7009
SecondaryPeak Expiratory Flow (PEF) Recorded at Home

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Home peak flow testing for PEF was performed every morning while sitting or standing prior to using any medication (if needed) for asthma. Mean PEF values for each week were reported starting from Day 1 to Day 84.

Time frame:
Day 1 to Day 84
Reported as:
Mean · liters per minute (L/min)
Peak Expiratory Flow (PEF) Recorded at Home
liters per minute (L/min)PlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Day 1 to 7161.845 ± 45.186179.000 ± 61.653177.929 ± 58.791
Day 8 to 14175.093 ± 50.914186.538 ± 52.945172.811 ± 59.941
Day 15 to 21169.489 ± 51.560180.627 ± 55.853180.362 ± 60.894
Day 22 to 28163.844 ± 57.753183.066 ± 54.902181.199 ± 62.497
Day 29 to 35163.999 ± 53.078179.064 ± 55.297171.458 ± 65.889
Day 36 to 42169.510 ± 57.745178.373 ± 51.881168.228 ± 64.673
Day 43 to 49171.373 ± 56.824185.847 ± 57.767169.727 ± 65.110
Day 50 to 56169.487 ± 58.325178.070 ± 57.414169.230 ± 62.696
Day 57 to 63169.723 ± 61.318176.761 ± 56.410169.374 ± 70.249
Day 64 to 70166.968 ± 57.401188.805 ± 59.186164.368 ± 66.619
Day 71 to 77160.717 ± 61.017175.379 ± 59.158160.167 ± 59.618
Day 78 to 84167.197 ± 58.690172.788 ± 56.722164.982 ± 60.271
SecondaryNumber of Puffs of Rescue Beta-2 Agonist Per Week

Rescue beta-2 agonist use (total number of puffs for the prior day) was collected daily in the morning by the participants in the electronic daily diary provided to them. Participants were instructed not to collect rescue beta-2 agonist used prior to exercise. Average values for each week were reported starting from Day 1 to Day 84.

Time frame:
Day 1 to Day 84
Reported as:
Mean · puffs per week
Number of Puffs of Rescue Beta-2 Agonist Per Week
puffs per weekPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Day 1 to 71.95 ± 1.751.74 ± 2.051.47 ± 1.76
Day 8 to 141.80 ± 2.011.63 ± 1.901.38 ± 2.07
Day 15 to 211.57 ± 2.002.01 ± 3.341.42 ± 1.70
Day 22 to 281.93 ± 2.651.83 ± 2.551.45 ± 1.76
Day 29 to 351.76 ± 2.791.62 ± 2.171.53 ± 1.73
Day 36 to 421.86 ± 3.361.42 ± 1.651.59 ± 1.92
Day 43 to 491.85 ± 3.531.33 ± 1.441.71 ± 2.05
Day 50 to 562.16 ± 4.831.52 ± 1.941.87 ± 2.32
Day 57 to 632.59 ± 6.631.43 ± 1.731.54 ± 1.56
Day 64 to 702.69 ± 6.431.50 ± 1.761.48 ± 1.65
Day 71 to 771.69 ± 1.961.39 ± 1.841.48 ± 1.44
Day 78 to 841.27 ± 1.562.04 ± 3.111.47 ± 1.41
SecondaryNumber of Participants With Physician Global Assessment (PGA) at Day 42 and Day 84

Physician Global Assessment (PGA) consisted of a single physician-rated question assessing participant's status as 'excellent', 'good', 'moderate', 'poor', 'worsening' or 'not applicable (NA)'. Number of participants were categorically summarized.

Time frame:
Days 42 and 84
Reported as:
Count of participants · Participants
Number of Participants With Physician Global Assessment (PGA) at Day 42 and Day 84
ParticipantsPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Day 42: Excellent91010
Day 42: Good121916
Day 42: Moderate837
Day 42: Poor332
Day 42: Worsening110
Day 42: Not applicable101
Day 84: Excellent81211
Day 84: Good151311
Day 84: Moderate739
Day 84: Poor341
Day 84: Worsening230
Day 84: Not applicable100
SecondaryAsthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Scores

Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ\[S\]): a 32-item questionnaire that measures the functional impairments experienced by adult participants including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment).

Time frame:
Days 0, 42, and 84
Reported as:
Mean · units on a scale
Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Scores
units on a scalePlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Overall: Day 03.14 ± 0.913.18 ± 0.953.35 ± 1.11
Overall: Day 424.74 ± 1.654.76 ± 1.465.16 ± 1.44
Overall: Day 844.91 ± 1.715.01 ± 1.445.11 ± 1.35
Symptoms: Day 02.84 ± 0.942.79 ± 1.083.11 ± 1.25
Symptoms: Day 424.77 ± 1.824.82 ± 1.455.19 ± 1.62
Symptoms: Day 844.94 ± 1.684.95 ± 1.535.09 ± 1.36
Activity limitation: Day 03.56 ± 0.973.74 ± 1.133.98 ± 1.29
Activity limitation: Day 424.96 ± 1.544.92 ± 1.515.30 ± 1.42
Activity limitation: Day 845.11 ± 1.745.23 ± 1.365.24 ± 1.44
Emotional function: Day 02.73 ± 1.252.44 ± 1.162.47 ± 1.48
Emotional function: Day 424.30 ± 1.964.35 ± 1.774.91 ± 1.66
Emotional function: Day 844.59 ± 2.044.59 ± 1.754.84 ± 1.73
Environmental stimuli: Day 03.35 ± 1.313.72 ± 1.293.42 ± 1.48
Environmental stimuli: Day 424.59 ± 1.694.63 ± 1.534.99 ± 1.44
Environmental stimuli: Day 844.69 ± 1.805.08 ± 1.625.13 ± 1.35
SecondaryNumber of Healthcare Resources Utilized by Resource Type

Healthcare resource use was summarized by resource type from information on asthma exacerbations, and asthma related medications. Healthcare resource utilization assessed the total number of hospitalizations, urgent care, primary care clinic visits, asthma specialist clinic visits, telephone calls, and home management.

Time frame:
Day 0 to Day 168
Reported as:
Number · healthcare resources
Number of Healthcare Resources Utilized by Resource Type
healthcare resourcesPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Hospitalizations644043
Urgent care200
Primary care clinic visits315
Asthma specialist clinic visits550
Telephone calls614
Home management214
SecondaryMaximum Observed Serum Concentration (Cmax) for Benralizumab

The Cmax of benralizumab is reported. Non-compartmental pharmacokinetic (PK) analysis was used for evaluation.

Time frame:
Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) for Benralizumab
microgram per milliliter (mcg/mL)Benralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Maximum Observed Serum Concentration (Cmax) for Benralizumab7.03 ± 1.7826.7 ± 6.49
SecondaryArea Under the Serum Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) for Benralizumab

AUClast = area under the concentration-time curve from time 0 to last measurable concentration. Non-compartmental PK analysis was used for evaluation.

Time frame:
Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84
Reported as:
Mean · microgram*day per milliliter
Area Under the Serum Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) for Benralizumab
microgram*day per milliliterBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Area Under the Serum Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) for Benralizumab65.7 ± 18.5263 ± 64.1
SecondaryArea Under the Serum Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUC [0 - Infinity]) for Benralizumab

AUC \[0 - infinity\] = Area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity). Non-compartmental PK analysis was used for evaluation.

Time frame:
Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84
Reported as:
Mean · microgram*day per milliliter
Area Under the Serum Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUC [0 - Infinity]) for Benralizumab
microgram*day per milliliterBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Area Under the Serum Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUC [0 - Infinity]) for Benralizumab67.1 ± 18.0268 ± 65.7
SecondarySystemic Clearance (CL) for Benralizumab

Systemic clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Non-compartmental PK analysis was used for evaluation. Clearance was normalized to participant's body weight.

Time frame:
Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84
Reported as:
Mean · milliliter per kilogram per day
Systemic Clearance (CL) for Benralizumab
milliliter per kilogram per dayBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Systemic Clearance (CL) for Benralizumab4.92 ± 1.963.97 ± 1.02
SecondaryTerminal Phase Elimination Half-Life (t1/2) for Benralizumab

Terminal phase elimination half-life is the time measured for the serum concentration to decrease by one half. Non-compartmental PK analysis was used for evaluation.

Time frame:
Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84
Reported as:
Mean · days
Terminal Phase Elimination Half-Life (t1/2) for Benralizumab
daysBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Terminal Phase Elimination Half-Life (t1/2) for Benralizumab11.5 ± 3.1413.2 ± 2.39
SecondaryVolume of Distribution of the Central Compartment (Vc) for Benralizumab

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Vc = volume of distribution of the central compartment, calculated as Dose/Cmax; where Cmax = maximum observed serum concentration. Non-compartmental PK analysis was used for evaluation. Results were normalized to participant's body weight.

Time frame:
Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84
Reported as:
Mean · milliliter per kilogram (mL/kg)
Volume of Distribution of the Central Compartment (Vc) for Benralizumab
milliliter per kilogram (mL/kg)Benralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Volume of Distribution of the Central Compartment (Vc) for Benralizumab46.4 ± 17.039.8 ± 10.3
SecondaryVolume of Distribution at Steady State (Vss) for Benralizumab

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Vss = steady state volume of distribution, calculated as MRT\*CL, where MRT is the Mean Residence Time and CL is systemic clearance; which is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Non-compartmental PK analysis was used for evaluation. Results were normalized to participant's body weight.

Time frame:
Predose and 1 hour post-end of infusion on Day 0; Days 7, 42, and 84
Reported as:
Mean · mL/kg
Volume of Distribution at Steady State (Vss) for Benralizumab
mL/kgBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Volume of Distribution at Steady State (Vss) for Benralizumab71.8 ± 23.264.0 ± 15.1
SecondaryNumber of Participants With Anti-Drug Antibodies to Benralizumab

Number of participants with anti-drug antibodies to benralizumab is reported.

Time frame:
Day 0 and 84
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies to Benralizumab
ParticipantsBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
Day 010
Day 8424

Adverse events

Collected over Day 0 to Day 84. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/38 (0%)9/38 (23.7%)28/38 (73.7%)
Benralizumab 0.3 mg/kg0/36 (0%)8/36 (22.2%)30/36 (83.3%)
Benralizumab 1.0 mg/kg0/36 (0%)11/36 (30.6%)28/36 (77.8%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
AsthmaRespiratory, thoracic and mediastinal disorders9/384/366/36
TachycardiaCardiac disorders0/380/361/36
Gastrointestinal haemorrhageGastrointestinal disorders0/381/360/36
OesophagitisGastrointestinal disorders0/381/360/36
PyrexiaGeneral disorders0/381/361/36
GastroenteritisInfections and infestations0/380/361/36
PneumoniaInfections and infestations0/381/360/36
Post procedural complicationInjury, poisoning and procedural complications0/380/361/36
Diabetes mellitusMetabolism and nutrition disorders0/381/360/36
AnxietyPsychiatric disorders0/380/361/36
Most frequent other events
Showing 10 of 121
Most frequent other events
EventPlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kg
AsthmaRespiratory, thoracic and mediastinal disorders18/3812/3614/36
HeadacheNervous system disorders4/385/369/36
CoughRespiratory, thoracic and mediastinal disorders3/381/366/36
DizzinessNervous system disorders1/385/363/36
DyspepsiaGastrointestinal disorders0/383/360/36
NauseaGastrointestinal disorders1/380/363/36
Blood creatinine increasedInvestigations0/380/363/36
BronchitisInfections and infestations3/382/362/36
Upper respiratory tract infectionInfections and infestations3/381/360/36
Back painMusculoskeletal and connective tissue disorders3/380/362/36

Baseline characteristics

Intent-to-treat population included all participants who were randomized into the study.

Age, Continuous
Age, Continuous(Years)PlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kgTotal
Mean35.9 ± 10.537.9 ± 11.434.8 ± 10.036.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kgTotal
Female30242377
Male8121333
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kgTotal
Hispanic or Latino62715
Not Hispanic or Latino32342995
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBenralizumab 0.3 mg/kgBenralizumab 1.0 mg/kgTotal
American Indian or Alaska Native1001
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American26191964
White11141641
More than one race0000
Unknown or Not Reported0213
08

Study locations

11 sites
  • Research Site
    Tampa, Florida 33613, United States
  • Research Site
    Springfield, Massachusetts 01199, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    East Meadow, New York 11554, United States
  • Research Site
    New Hyde Park, New York 11040, United States
  • Research Site
    Stony Brook, New York 11794-8350, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Cleveland, Ohio 44109, United States
  • Research Site
    Providence, Rhode Island 2903, United States
  • Research Site
    Edmonton, Alberta T6G 2R3, Canada
  • Research Site
    Halifax, Nova Scotia B3H 3A7, Canada
09

References and documents

Publications

  • Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Molfino NA. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015 Jan;33(1):14-20. doi: 10.1016/j.ajem.2014.09.036. Epub 2014 Oct 5. PubMed 25445859 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Dec 2010, 22 months.

Results were first posted in Oct 2020, 9 years 9 months after primary completion. A results delay was requested in Jul 2016.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 22 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2008
First posted
Oct 7, 2008
StartActual
Feb 2, 2009
Primary completionActual
Dec 17, 2010
CompletionActual
Mar 10, 2011
Results delay requested
Jul 14, 2016
Results first posted
Oct 12, 2020
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00768079
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 7, 2008
Start date
Feb 2, 2009
Primary completion
Dec 17, 2010
Completion
Mar 10, 2011
Results posted
Oct 12, 2020
Last update
Nov 18, 2020

Study contacts

Joseph M. Parker, M.D.
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion